Range of values for lipid accumulation product (LAP) in healthy residents of the European north of Russia

BACKGROUND: Obesity is a major health problem in modern society and its prevalence throughout the world has reached the epidemic level. The unfavorable outcomes of obesity are associated with a high risk of numerous diseases due to metabolic disorders. Finding of diagnostic criteria for early detection of obesity is a priority in biomedical research. Therefore, of particular interest is the new visceral obesity marker – lipid accumulation product (LAP). Meanwhile, to date, the reference values for LAP are not defined, and data on sex- and age-related changes are contradictory.

AIMS: The aim of this study was to determine the variation range, sex and age differences in LAP values in healthy subjects.

MATERIALS AND METHODS: The study was conducted on apparently healthy subjects (455 men and 286 women) aged 20–59 years selected at routine examinations at the base of the central clinic in Arkhangelsk. Examination of subjects consisted of physical examination with measurement of anthropometric and clinical parameters, filling out a questionnaire, and evaluation of serum lipid levels.

RESULTS: The LAP values in the subjects varied in a wide range (0.5–156.5 cm×mmol/l in men; 0.4 to 116.2 cm×mmol/l in women), but at the same they in 75% of the participants did not exceed 30 cm×mmol/l. Sex differences in LAP with the prevalence of values in men were observed in the age groups up to 40 years old, later they disappeared. LAP in men and women increased with age, but these changes were unequal. The LAP values increased to reach a plateau in men up to 30 years of age and in women up to 40 years of age.

CONCLUSIONS: LAP is a combined index that simultaneously reflects distribution of adipose tissue and changes in blood lipids, and is considered a marker of obesity associated with the risk of metabolic disorders. This study was the first to determine the variation range, sex differences and age dynamics for LAP in the apparently healthy subjects.

lipid accumulation product (LAP), body mass index (BMI), obesity, waist circumference, triglycerides, atherogenicity, metabolism

1. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581-1586. DOI:10.1001/archinte.161.13.1581

2. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-2971. DOI:10.1093/eurheartj/ehn387

3. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89(2):447-452. DOI:10.1210/jc.2003-031005

4. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11-18. DOI:10.1111/j.1467-789X.2009.00623.x

5. Сагирова Р.И., Вербовой А.Ф. Инсулинорезистентность – основа сахарного диабета 2-го типа // РМЖ. — 2017. — Т. 25. — №14. — С. 1039-1042. [Sagirova RI, Verbovoy AF. Insulinorezistentnost’ – osnova saharnogo diabeta 2-go tipa. RMZh. 2017;25(14):1039-1042. (In Russ.)]

6. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. DOI:10.1152/physrev.00033.2011

7. Kahn HS. The lipid accumulation product is better than body mass index for identifying diabetes. Am J Epidemiol. 2005;161(11):S51.

8. Lwow F, Jedrzejuk D, Milewicz A, Szmigiero L. Lipid accumulation product (LAP) as a criterion for the identification of the healthy obesity phenotype in postmenopausal women. Exp Gerontol. 2016;82:81-87. DOI:10.1016/j.exger.2016.06.007

9. Du T, Yu X, Zhang J, Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype. Acta Diabetol. 2015;52(5):855-863. DOI:10.1007/s00592-015-0715-2

10. Ray L, Ravichandran K, Nanda SK. Comparison of lipid accumulation product index with body mass index and waist circumference as a predictor of metabolic syndrome in Indian population. Metab Syndr Relat Disord. 2018;16(5):240-245. DOI:10.1089/met.2017.0119

11. Xia C, Li R, Zhang S, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66(9):1035-1038. DOI:10.1038/ejcn.2012.83

12. Wang H, Chen Y, Sun G, et al. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med. 2018;130(3):325-333. DOI:10.1080/00325481.2018.1444901

13. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98. DOI:10.1186/1471-230X-10-98

14. Bozorgmanesh M, Hadaegh F, Azizi F. Diabetes prediction, lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9:45. DOI:10.1186/1476-511X-9-45

15. Motamed N, Razmjou S, Hemmasi G, et al. Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest. 2016;39(4):375-382. DOI:10.1007/s40618-015-0369-5

16. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583-588. DOI:10.1016/s0009-9120(01)00263-6

17. Omuse G, Maina D, Hoffman M, et al. Metabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study. BMC Endocr Disord. 2017;17:37. DOI:10.1186/s12902-017-0188-0

18. Rotter I, Rył A, Szylińska A, et al. Lipid Accumulation Product (LAP) as an Index of Metabolic and Hormonal Disorders in Aging Men. Exp Clin Endocrinol Diabetes. 2017;125(3):176-182. DOI:10.1055/s-0042-116071

19. Oh JY, Sung YA, Lee HJ. The lipid accumulation product as a useful index for identifying abnormal glucose regulation in young Korean women. Diabet Med. 2013;30(4):436-442. DOI:10.1111/dme.12052

20. Драпкина О.М., Шепель Р.Н., Шальнова С.А., и др. Основные антропометрические индексы и сахарный диабет 2 типа в российской популяции // Рациональная фармакотерапия в кардиологии. — 2018. — Т. 14. — №5. — С. 725-732. [Drapkina OM, Shepel RN, Shalnova SA, et al. Basic anthropometric indices and diabetes mellitus type 2 in Russian population. Rational pharmacotherapy in cardiology. 2018;14(5):725-732. (In Russ.)] DOI:10.20996/1819-6446-2018-14-5-725-732

21. Хрипун И.А., Воробьев С.В., Коган М.И. Новый маркер метаболических нарушений у мужчин с сахарным диабетом 2 типа // Медицинский вестник Юга России. — 2016. — №1. — С. 84-86. [Khripun IA, Vorobev SV, Kogan MI. A new marker of metabolic disorders in men with type 2 diabetes. Meditsinskiy vestnik Yuga Rossii. 2016;(1):84-86. (In Russ.)]

22. Корноухова Л.А. Значение предикторов кардиоваскулярных нарушений у пациентов с абдоминальным ожирением, неалкогольной жировой болезнью печени и различными компонентами метаболического синдрома // Медицинский алфавит. — 2017. — Т. 1. — №6. – С. 51-56. [Kornoukhova L.A. Value of cardiovascular disorders’ predictors in patients with abdominal obesity, nonalcoholic fatty liver disease and various metabolic syndrome components. Meditsinskii alfavit. 2017;1(6):51-56. (In Russ.)]

23. Wakabayashi I. Influence of age and gender on lipid accumulation product and its relation to diabetes mellitus in Japanese. Clin Chim Acta. 2014;431:221-226. DOI:10.1016/j.cca.2014.02.002

24. Cartolano FC, Pappiani C, Freitas MCP, et al. Is lipid accumulation product associated with an atherogenic lipoprotein profile in Brazilian subjects? Arq Bras Cardiol. 2018;110(4):339-347. DOI:10.5935/abc.20180054

25. Мешков А.Н., Ершова А.И., Деев А.Д., и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в российской федерации: результаты исследования ЭССЕ-РФ за 2012-2014 гг // Кардиоваскулярная терапия и профилактика. — 2017. — Т. 16. — №4. — С. 62-67. [Meshkov AN, Ershova АI, Deev АD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the ESSE-RF study for the years 2012-2014. Cardiovascular therapy and prevention. 2017;16(4):62-67. (In Russ.)] DOI:10.15829/1728-8800-2017-4-62-67

26. Kahn HS, Bullard KM, Barker LE, Imperatore G. Differences between adiposity indicators for predicting all-cause mortality in a representative sample of United States non-elderly adults. PLoS One. 2012;7(11):e50428. DOI:10.1371/journal.pone.0050428

27. Fu S, Luo L, Ye P, Xiao W. Multimarker analysis for new biomarkers in relation to central arterial stiffness and hemodynamics in a Chinese community-dwelling population. Angiology. 2015;66(10):950-956. DOI:10.1177/0003319715573910

28. Joshi H, Shah K, Patel P, et al. Novel indexes for diagnosing metabolic syndrome in apparently healthy Gujarati Asian Indians: a cross-sectional study. QJM. 2016;109(11):717-722. DOI:10.1093/qjmed/hcw056